Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109,… Read more
Sionna Therapeutics, Inc. Common Stock (SION) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.047x
Based on the latest financial reports, Sionna Therapeutics, Inc. Common Stock (SION) has a cash flow conversion efficiency ratio of -0.047x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.23 Million) by net assets ($321.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sionna Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Sionna Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sionna Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sionna Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Browave
TWO:3163
|
0.043x |
|
Lotus Retail Growth Freehold and Leasehold Property Fund
BK:LPF
|
0.018x |
|
Télévision Française 1 Société anonyme
PINK:TVFCF
|
0.062x |
|
NEW HORIZ.HEAL. DL-00005
F:6YZ
|
N/A |
|
Shenzhen Bingchuan Network Co Ltd
SHE:300533
|
0.009x |
|
Chennai Petroleum Corporation Limited
NSE:CHENNPETRO
|
0.158x |
|
Green Cross Corp
KO:006280
|
0.094x |
|
Heiwa Corporation
F:HWC
|
0.024x |
Annual Cash Flow Conversion Efficiency for Sionna Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Sionna Therapeutics, Inc. Common Stock from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-163.71 Million | $-52.79 Million | 0.322x | -15.23% |
| 2023-12-31 | $-114.88 Million | $-43.70 Million | 0.380x | -26.26% |
| 2022-12-31 | $-69.92 Million | $-36.07 Million | 0.516x | -- |